(secondQuint)Thalidomide in Treating Patients With Metastatic Neuroendocrine Tumors.

 OBJECTIVES: - Determine the safety and efficacy of thalidomide in patients with metastatic low-grade neuroendocrine tumors.

 OUTLINE: Patients receive oral thalidomide once daily on weeks 1-8.

 Courses repeat every 8 weeks in the absence of disease progression or unacceptable toxicity.

 PROJECTED ACCRUAL: A total of 14-25 patients will be accrued for this study.

.

 Thalidomide in Treating Patients With Metastatic Neuroendocrine Tumors@highlight

RATIONALE: Thalidomide may stop the growth of neuroendocrine tumors by stopping blood flow to the tumor.

 PURPOSE: Phase II trial to study the effectiveness of thalidomide in treating patients who have metastatic neuroendocrine tumors.

